Adaptive Biotechnologies Q2 revenue rises 22%, beats estimates

Adaptive Biotechnologies

29/07/2026 21:23

Overview
US biotechnology firm's Q2 revenue rose 22% yr/yr, beating analyst expectations
Q2 adjusted EBITDA loss narrowed and beat analyst estimates
Company raised full-year MRD revenue guidance and plans to separate MRD and Immune Medicine units

Outlook
Adaptive Biotechnologies raises 2026 MRD revenue guidance to $268 mln-$278 mln
Company revises full-year operating expense guidance to $350 mln-$355 mln
No revenue guidance provided for Immune Medicine business

Result Drivers
MRD BUSINESS GROWTH - MRD business revenue rose 33% yr/yr and made up 92% of total revenue
CLONOSEQ TEST VOLUME - clonoSEQ test volume increased 43% yr/yr to 36,111 tests delivered
IMMUNE MEDICINE DECLINE - Immune Medicine revenue fell 40% yr/yr, though excluding Genentech Agreement, revenue rose 8%

Company press release: ID:nGNX7VJvDq

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$71.55 mln
$65.89 mln (7 Analysts)
Q2 Loss Per Share
 
$0.25
 
Q2 Net Loss
 
$39.94 mln
 
Q2 Adjusted EBITDA
Beat
-$726,000
-$4.32 mln (3 Analysts)
Q2 Operating Expenses
 
$87.32 mln
 
Q2 Operating Income
 
-$15.77 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Adaptive Biotechnologies Corp is $21.00, about 6.7% below its July 28 closing price of $22.52

Reuters Recommended Reads
July 28 - NeoGenomics Q2 revenue beats estimates, raises outlook
July 29 - Biogen beats quarterly estimates as newer drugs drive growth
July 29 - Ionis Q2 adjusted operating loss narrows

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)